BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/22/2023 4:14:47 AM | Browse: 150 | Download: 500
 |
Received |
|
2023-07-13 19:45 |
|
Peer-Review Started |
|
2023-07-13 20:33 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2023-09-26 09:19 |
|
Revised |
|
2023-10-13 22:33 |
|
Second Decision |
|
2023-10-27 07:55 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2023-10-30 07:30 |
|
Articles in Press |
|
2023-10-30 07:30 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2023-11-16 05:30 |
|
Publish the Manuscript Online |
|
2023-11-22 04:14 |
| ISSN |
2218-4333 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Oncology |
| Manuscript Type |
Case Report |
| Article Title |
Autoimmune diabetes from pembrolizumab: A case report and review of literature
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hardikkumar Bhanderi, Farhan Khalid, Zubair Hassan Bodla, Tayyeb Muhammad, Doantrang Du and Trishala Meghal |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Hardikkumar Bhanderi, MD, Staff Physician, Internal Medicine, Monmouth Medical Center, 300 2nd Avenue, Long branch, NJ 07740, United States. dr.hardikkumar.bhanderi@gmail.com |
| Key Words |
Pembrolizumab; Breast cancer; Autoimmune diabetes; Keytruda; Immunotherapy; Case report |
| Core Tip |
Our review highlights an important and rare adverse effect of Pembrolizumab. We have also reviewed the number of cycles patients were treated with Keytruda before the onset of diabetes. Clinicians should be watchful for the signs and symptoms. Early discontinuation of immunotherapy is needed to prevent significant morbidity and mortality. |
| Publish Date |
2023-11-22 04:14 |
| Citation |
Bhanderi H, Khalid F, Bodla ZH, Muhammad T, Du D, Meghal T. Autoimmune diabetes from pembrolizumab: A case report and review of literature. World J Clin Oncol 2023; 14(11): 535-543 |
| URL |
https://www.wjgnet.com/2218-4333/full/v14/i11/535.htm |
| DOI |
https://dx.doi.org/10.5306/wjco.v14.i11.535 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
